Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 5,277 matching trials from the live ClinicalTrials.gov search.

Filters: Gainesville, Florida Clear all

Conditions: Subarachnoid Haemorrhage
Interventions: placebo, simvastatin; Drug
Lead sponsor: Cambridge University Hospitals NHS Foundation Trust; Other
Eligibility: 18 Years to 65 Years
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Hepatitis C Virus
Interventions: Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 33
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more

Conditions: Osteonecrosis
Interventions: Observational; Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 90 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Selpercatinib; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 306
States / cities: Fairbanks, Alaska • Little Rock, Arkansas • Anaheim, California + 251 more

Conditions: Nerve Block, Pain
Interventions: Receive ICBN with ropivacaine, No ICBN block; Drug · Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Osteoarthritis, Hypertension
Interventions: naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen 500 mg bid, ibuprofen 600 mg tid; Drug
Lead sponsor: NicOx; Industry
Eligibility: 40 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 57
States / cities: Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 54 more

Conditions: Postmenopausal Osteoporosis
Interventions: risedronate; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 923 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 20
States / cities: Birmingham, Alabama • Oakland, California • San Diego, California + 16 more

Conditions: THROMBOLYSIS
Interventions: Tenecteplase, Placebo; Biological · Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 94
States / cities: Birmingham, Alabama • Mesa, Arizona • Anaheim, California + 74 more

Conditions: Advanced Solid Tumor
Interventions: AI-081; Drug
Lead sponsor: OncoC4, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Birmingham, Alabama • Springdale, Arkansas • Washington D.C., District of Columbia + 18 more

Conditions: Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions: PPD10558, Atorvastatin, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 67
States / cities: Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more

Conditions: Rheumatoid Arthritis
Interventions: CC-292, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 24 more

Conditions: Cholangiocarcinoma
Interventions: Pemigatinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 49
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tempe, Arizona + 46 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GALIDA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 64
States / cities: Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 61 more

Conditions: Muscular Dystrophy, Duchenne
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 7 Years to 14 Years · Male only
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 23
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 20 more

Conditions: Acute Coronary Syndrome, High Bleeding Risk
Interventions: BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug; Device · Drug
Lead sponsor: Biosensors Europe SA; Industry
Eligibility: Not listed
Enrollment: 1,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 39
States / cities: Huntsville, Alabama • Hot Springs, Arkansas • La Jolla, California + 34 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol, Fluticasone Propionate/Salmeterol Combination Product; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more

Conditions: Leukemia
Interventions: cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 9 Years
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 108
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more

Conditions: Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Procedure · Other · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 895
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 637 more

Conditions: Prader-Willi Syndrome
Interventions: DCCR, Placebo for DCCR; Drug
Lead sponsor: Soleno Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: Orange, California • Palo Alto, California • San Diego, California + 17 more

Conditions: Radiculopathy, Myelopathy, Cervical Degenerative Disc Disease
Interventions: ATLANTIS™ Cervical Plate System and allograft, BRYAN Cervical Disc Prosthesis; Device
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 21 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 38
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Campbell, California + 31 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: Faster-acting insulin aspart, insulin aspart, insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 834 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 38
States / cities: Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 32 more

Conditions: Ischemic Heart Disease
Interventions: Eplerenone, Placebo or sugar pill; Drug
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Enteric Hyperoxaluria
Interventions: Reloxaliase, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 64
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 57 more

Conditions: Carcinoma
Interventions: Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, Treatment determined by physician; Drug · Other
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 21
States / cities: Huntsville, Alabama • Fort Myers, Florida • Jacksonville, Florida + 18 more

Search by objective public record fields.

Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Intercostobrachial Nerve Block (ICBN) for Tourniquet Pain: Is it Necessary?

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

Tenecteplase in Stroke Patients Between 4.5 and 24 Hours

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

GALLANT 5 Tesaglitazar Versus Metformin

A Study of Tadalafil for Duchenne Muscular Dystrophy

LEADERS FREE II: BioFreedom™ Pivotal Study

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria

Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site